SELLAS Life Sciences (SLS) Interest & Investment Income (2010 - 2026)
SELLAS Life Sciences (SLS) reported Interest & Investment Income of $845000.0 for Q1 2026, up 238.0% year-over-year from $250000.0 in Q1 2025, and up 41.54% on a QoQ basis from $597000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 9 years of Interest & Investment Income data on file, last reported at $845000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 238.0% year-over-year to $845000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 149.81% YoY) and the FY2025 annual result came in at $1.4 million, up 123.26% from the prior year.
- Interest & Investment Income advanced to $845000.0 in Q1 2026 per SLS's latest filing, from $597000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $845000.0 in Q1 2026 and bottomed at $41000.0 in Q4 2023.
- The 4-year median for Interest & Investment Income is $214500.0 (2023), against an average of $269250.0.
- Peak annual rise in Interest & Investment Income reached 341.46% in 2024, while the deepest fall reached 27.4% in 2024.
- Tracing SLS's Interest & Investment Income over 4 years: stood at $41000.0 in 2023, then jumped by 341.46% to $181000.0 in 2024, then jumped by 229.83% to $597000.0 in 2025, then jumped by 41.54% to $845000.0 in 2026.
- Per Business Quant, the three latest SLS Interest & Investment Income figures stand at $845000.0 (Q1 2026), $597000.0 (Q4 2025), and $292000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 845,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 597,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Jun 30, 2014 | -491,000.00 |
| Dec 31, 2013 | -312,000.00 |
| Sep 30, 2013 | -314,000.00 |
| Jun 30, 2013 | 634,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Dec 31, 2012 | 2,000.00 |
| Jun 30, 2012 | -19,000.00 |
| Mar 31, 2012 | -16,000.00 |
| Dec 31, 2011 | -1,000.00 |
| Sep 30, 2011 | -2,000.00 |
| Jun 30, 2011 | -3,000.00 |
| Mar 31, 2011 | -1,000.00 |
| Sep 30, 2010 | 3,000.00 |
| Jun 30, 2010 | 3,000.00 |